Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment?

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 202-206

  Roubille, François ^a,b,c   Lattuca, Benoît ^b,c   Busseuil, David ^a   Leclercq, Florence ^b   Davy, Jean Marc ^b   Rhéaume, Eric ^a,d   Tardif, Jean Claude ^a,d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DOBUTAMINE; IVABRADINE; MINERALOCORTICOID ANTAGONIST;

ACTION POTENTIAL; ARTICLE; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DISEASE CONTROL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPERPOLARIZATION; HYPOTHESIS; INOTROPISM; MULTIPLE ORGAN FAILURE; SINUS TACHYCARDIA;

ACE; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN II RECEPTOR ANTAGONIST; ARB; BEATS PER MINUTE; BPM; HCN; HEART FAILURE; HEART RATE; HF; HR; HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; LEFT VENTRICULAR EJECTION FRACTION; LVEF; MINERALOCORTICOID RECEPTOR ANTAGONIST; MODS; MRA; MULTIPLE ORGAN DYSFUNCTION SYNDROME;

BENZAZEPINES; DOBUTAMINE; HUMANS; MODELS, THEORETICAL; TACHYCARDIA;

EID: 84880042725     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.05.002     Document Type: Article

References (40)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
2. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-1847.
3. Partovian C., Gleim S.R., Mody P.S., et al. Hospital Patterns of Use of Positive Inotropic Agents in Patients With Heart Failure. Journal of the American College of Cardiology 2012, 60:1402-1409.
4. Leier C.V., Webel J., Bush C.A. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977, 56:468-472.
5. Vasquez A., Kern K.B., Hilwig R.W., Heidenreich J., Berg R.A., Ewy G.A. Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction. Resuscitation 2004, 61:199-207.
6. Kulka P.J., Tryba M. Inotropic support of the critically ill patient. A review of the agents. Drugs 1993, 45:654-667.
7. Caldicott L.D., Hawley K., Heppell R., Woodmansey P.A., Channer K.S. Intravenous enoximone or dobutamine for severe heart failure after acute myocardial infarction: a randomized double-blind trial. Eur Heart J 1993, 14:696-700.
8. Silver M.A., Horton D.P., Ghali J.K., Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002, 39:798-803.
9. Tisdale J.E., Patel R., Webb C.R., Borzak S., Zarowitz B.J. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995, 38:167-180.
10. Tardif J.C., O'Meara E., Komajda M., et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011, 32:2507-2515.
11. Roubille F., Tardif J.C. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation 2013, 127:1986-1996.
12. Gardiner S.M., Kemp P.A., March J.E., Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol 1995, 115:579-586.
13. DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010, 106:434-446.
14. DiFrancesco D., Camm J.A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004, 64:1757-1765.
15. Ragueneau I., Laveille C., Jochemsen R., Resplandy G., Funck-Brentano C., Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998, 64:192-203.
16. Manz M., Reuter M., Lauck G., Omran H., Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003, 100:149-155.
17. Tardif J.C., Ponikowski P., Kahan T., Investigators A.S. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009, 30:540-548.
18. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R., Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
19. Beautiful Study Group, Ferrari R., Ford I., Fox K., Steg P.G., Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology 2008, 110:271-282.
20. Tardif J.C. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today 2008, 44:171-181.
21. Zhang R., Bobylev D., Stiefel P., Haverich A., Bara C. Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol 2012, 101:631-636.
22. Zhang R., Haverich A., Struber M., Simon A., Pichlmaier M., Bara C. Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 2008, 97:811-819.
23. Zwicker C., Becker M., Lepper W., Koch K.C., Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology 2010, 116:174-177.
24. Lage-Galle E., Romero-Rodriguez N., Nevado-Portero J., et al. Safety and effectiveness of ivabradine after cardiac transplantation. Transpl Proc 2010, 42:3191-3192.
25. Calo L., Rebecchi M., Sette A., et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010, 7:1318-1323.
26. McDonald C., Frith J., Newton J.L. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace 2011, 13:427-430.
27. Link A., Reil J.C., Selejan S., Bohm M. Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clinical Res Cardiol 2009, 98:513-515.
28. Vitale D., De Santis V., Guarracino F., Fontana A., Pellegrini F., Tritapepe L. Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clinical Res Cardiol 2010, 99:853-855.
29. Nuding S., Ebelt H., Hoke R.S., et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clinical Res Cardiol 2011, 100:915-923.
30. Aidonidis I., Brachmann J., Rizos I., et al. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion. Cardiovasc Drugs Ther 1995, 9:555-563.
31. Traunecker W., Walland A. Haemodynamic and electrophysiologic actions of alinidine in the dog. Arch Int Pharmacodyn Ther 1980, 244:58-72.
32. Wynsen J.C., O'Brien P.D., Warltier D.C. Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium. J Am Coll Cardiol 1994, 23:233-241.
33. Hettrick D.A., Pagel P.S., Lowe D., Tessmer J.P., Warltier D.C. Increases in inotropic state without change in heart rate: combined use of dobutamine and zatebradine in conscious dogs. Eur J Pharmacol 1996, 316:237-244.
34. Neustein S.M., Dimich I., Shiang H., Mezrow C. Role of zatebradine and propranolol in attenuation of tachycardia produced by dobutamine in pigs. Acta Anaesthesiol Scand 1997, 41:849-852.
35. Zhang Y., Mazgalev T.N. Cardiac vagal stimulation eliminates detrimental tachycardia effects of dobutamine used for inotropic support. Ann Thorac Surg 2009, 88:117-122.
36. Busseuil D., Shi Y., Mecteau M., et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 2010, 117:234-242.
37. Becher P.M., Lindner D., Miteva K., et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension 2012, 59:949-957.
38. Khoueiry Z., Roubille C., Nagot N., et al. Could heart rate play a role in pericardial inflammation?. Med Hypotheses 2012, 79:512-515.
39. Bolduc V., Drouin A., Gillis M.A., et al. Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol 2011, 301:H2081-2092.
40. Drouin A., Gendron M.E., Thorin E., Gillis M.A., Mahlberg-Gaudin F., Tardif J.C. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008, 154:749-757.